Melanoma acral lentiginoso, revisión bibliográfica
DOI:
https://doi.org/10.30944/20117582.412Palabras clave:
melanoma, interferón-alfa, quimioterapia, radioterapia, cirugíaResumen
El melanoma acral lentiginoso es el tipo de melanoma de localización distal más frecuente, suele diagnosticarse en los estadios más avanzados y tiene un comportamiento biológico más agresivo que otros tipos de melanoma, por lo cual son de peor pronóstico. Representa entre el 5 % y el 10 % de los melanomas malignos y es más frecuente en asiáticos, en la raza negra y en latinoamericanos. El objetivo de este artículo fue hacer una revisión bibliográfica actualizada con el fin de conocer las tasas de incidencia del tumor, los nuevos avances con respecto a los factores de riesgo, biología molecular, diagnóstico y tratamiento, y el desarrollo de nuevos tratamientos en el manejo del melanoma avanzado y metastásico.
Descargas
Referencias bibliográficas
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29. https://doi.org/10.3322/caac.20138
Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3-9. https://doi.org/10.1016/j.clindermatol.2008.09.001
Schmerling RA, Loria D, Cinat G, Ramos WE, Cardona AF, Sánchez JL, et al. Cutaneous melanoma in Latin America: The need for more data. Rev Panam Salud Pública. 2011;30:431-8. https://doi.org/10.1590/S1020-49892011001100005
Instituto Nacional de Cancerología. Anuario estadístico 2010. Fecha de consulta: 3 de mayo 2012. Disponible en: /http. incancerologia.gov.co.
Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687-701. https://doi.org/10.1016/S0140-6736(05)70937-5
Kuchemeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in Caucasians: Clinical features, histopathology and prognosis in 112 patients. Br J Dermatol. 2000;143:275- 80. https://doi.org/10.1046/j.1365-2133.2000.03651.x
Phan A, Touzet S, Dalle S, Ronger-Savlé S, Balme B, Thomas L. Acral lentiginous melanoma: A clinic-prognostic study of 126 cases. Br J Dermatol. 2006;155:561-9. https://doi.org/10.1111/j.1365-2133.2006.07368.x
Chamberlain A, Jonhatan NG. Cutaneous melanoma: A typical variants and presentations. Aust Fam Physician. 2009;38:476- 82.
Puig-Butillé J. Genetic alterations in RAS regulated pathway in acral lentiginous melanoma. Exp Dermatol. 2013;22:148-50. https://doi.org/10.1111/exd.12080
Nagore E, Pereda C. Botella-Estrada, Requena C, Guillén C. Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. Cancer Causes Control. 2009;20:115-9. https://doi.org/10.1007/s10552-008-9221-y
O'Leary JA, Berend KR, Johnson JL, Levin LS, Seigler HF. Subungual melanoma: A review of 93 cases with identification of prognostic variables. Clin Orthop Relat Res. 2000;378: 206-12. https://doi.org/10.1097/00003086-200009000-00031
Nestle FO. Halpern AC. Neoplasm of the skin. Dermatology. Second edition. Madrid: Mosby; 2008. p. 1745-69.
Balch CM, Urist MM, Maddox WA, Soong SJ. Melanoma in the Southern United States. In: Balch CM, Milton WG, editors. Cutaneos melanoma: Clinical management and treatment results worldwide. Philadelphia, PA: JB Lippincott, 1985. p. 397-406.
Durbec F, Martin L, Derancourt C, Grange F. Melanoma of the hand and foot: Epidemiological, prognostic and genetic features. A systematic review. Br J Dermatol. 2012;166:727-39. https://doi.org/10.1111/j.1365-2133.2011.10772.x
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206. https://doi.org/10.1200/JCO.2009.23.4799
Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Colt DG, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: An analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199-205. https://doi.org/10.1200/JCO.2010.31.5812
Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, et al. Prognosis of acral melanoma: A series of 281 patients. Ann Surg Oncol. 2013;20:3618-25. https://doi.org/10.1245/s10434-013-3089-0
Bradford P. Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145:427-34. https://doi.org/10.1001/archdermatol.2008.609
Rex J, Paradelo C, Mangas C, Hilari JM, Fernández-Figueras MT, Ferrándiz C. Management of primary cutaneous melanoma of the hands and feet: a clinic-prognostic study. Dermatol Surg. 2009;35:1505-13. https://doi.org/10.1111/j.1524-4725.2009.01265.x
Takata M. Acral melanoma: Clinical, biologic and molecular genetic characteristics. En: Murph M, editor. Melanoma in the clinic: Diagnosis, management and complications of malignancy. InTech. 2011;3-14. https://doi.org/10.5772/20251
Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De GiorgiV, et al. BRAF/NRAS mutation among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522-9. https://doi.org/10.1200/JCO.2011.41.2452
Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878-80. https://doi.org/10.1093/jnci/djg123
Saldanha G, Potter L, Daforno P, Pringle JH. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res. 2006;12:4499-505. https://doi.org/10.1158/1078-0432.CCR-05-2447
Ashida A, Takata M, Murata H, Kido K, Saida T. Pathological activation of KIT in metastasic tumors of acral and mucosal melanomas. Int J Cancer. 2009;124:863-8. https://doi.org/10.1002/ijc.24048
Marrero B, Shirley S, Heller R. Delivery of interleukin-15 to B16 melanoma by electroporation leads to tumor re gression and long-term survival. Technol Cancer Res Treat. 2013. Fecha de consulta: 22 de febrero de 2014. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24000979. DOI:10.7785/tcrtexpress.2013.600252. https://doi.org/10.7785/tcrtexpress.2013.600252
Ibrahim ZA. Cyclin D1 expression in acral melanoma: A case control study in Sarawak. Malays J Pathol. 2012;34:89-95.
Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, et al. Early diagnosis of cutaneous melanoma: Revisiting the ABCDE criteria. JAMA. 2004;292:2771-6. https://doi.org/10.1001/jama.292.22.2771
Soon SL, Salomon Jr AR, Papadopoulos D, Murray DR, McAlpine B, Washington CV. Acral lentiginous melanoma mimicking benign disease: The Emory experience. J Am Acad Dermatol. 2003;48:183-8. https://doi.org/10.1067/mjd.2003.63
Pereda C. Clinical presentation of acral lentiginous melanoma: A descriptive study. Actas Dermosifiliogr. 2013;104:220-6. doi: 10.1016/j.ad.2012.06.006. https://doi.org/10.1016/j.ad.2012.06.006
Pflugfelder A, Weide B, Eigentler TK, Forschner A, Leiter U, Held L, et al. Incisional biopsy and melanoma prognosis: Facts and controversies. Clin Dermatol. 2010;28:316-8. https://doi.org/10.1016/j.clindermatol.2009.06.013
Takata M, Saida T. Early cancers of the skin: Clinical, histopathological, and molecular characteristics. Int J Clin Oncol. 2005;10:391-7. https://doi.org/10.1007/s10147-005-0532-7
Bertolotto C. Melanoma: From melanocyte to genetic alterations and clinical options. Scientifica. 2013; Article ID 635203. https://doi.org/10.1155/2013/635203
Bastian BC. Targeting activated KIT signaling for melanoma therapy. J Clin Oncol . 2013;31:3288-90. https://doi.org/10.1200/JCO.2013.50.3227
Edge S, Byrd DR, Compton CC. Melanoma of the skin. AJCC Cancer Staging Manual. 7th edition. New York. Springer; 2010. p. 325-44. https://doi.org/10.1007/978-0-387-88441-7_31
Trotter S. A global review of melanoma follow-up guidelines. J Clin Aesthet Dermatol. 2013;6:18-26.
Moehrle M, Metzger S, Schippert W, Garbe C, Rassner G, Breuninger H. "Functional" surgery in subungual melanoma. Dermatol Surg. 2003;29:366-74. https://doi.org/10.1046/j.1524-4725.2003.29087.x
Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington (2008). Fecha de consulta: 29 de mayo de 2014. Disponible en: www.cancer.org.au/skincancerguides .
Morton DL. Overview and update on the first and second Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis. 2012;29:699-706. https://doi.org/10.1007/s10585-012-9503-3
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17. https://doi.org/10.1056/NEJMoa060992
Eggermont AM, Suciu S, Testori A, Kruit W, Marsden J, Punt C, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012;48:218-25. https://doi.org/10.1016/j.ejca.2011.09.028
Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998-1042. https://doi.org/10.1056/NEJMra041245
Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy formelanoma. Cancer J. 2012;18;192-202. https://doi.org/10.1097/PPO.0b013e31824f118b
Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011;22:787-93. https://doi.org/10.1093/annonc/mdq438
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF-V600E mutation. N Engl J Med. 2011;364:2507-16. https://doi.org/10.1056/NEJMoa1103782
Hauschild JJ, Grob LV, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open label, phase 3 randomized controlled trial. Lancet. 2012;380:358-65. https://doi.org/10.1016/S0140-6736(12)60868-X
Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol. 2007;14:230-8. https://doi.org/10.1245/s10434-006-9040-x
Moreno-Ramírez D. Isolated limb perfusion for malignant melanoma: Systematic review on effectiveness and safety. Oncologist. 2010;15:416-27. doi: 10.1634/theoncologist. 2009-0325. https://doi.org/10.1634/theoncologist.2009-0325
Coleman A. Optimizing regional infusion treatment strategies for melanoma of the extremities. Expert Rev Anticancer Ther. 2009;9:1599-609. doi: 10.1586/era.09.126. https://doi.org/10.1586/era.09.126
Ballo MT, Ang KK. Malignant melanoma. In: Gunderson L, Tepper J. editors. Clinical radiation oncology. Second edition. Philadelphia: Churchill Livingstone; 2007. p. 865-77.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23. https://doi.org/10.1056/NEJMoa1003466
Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, et al. Prognosis of acral melanoma: A series of 281 patients. Ann Surg Oncol. 2013;20:3618-25. https://doi.org/10.1245/s10434-013-3089-0
Kosmidis C, Efthimiadis C, Anthimidis G, Grigoriou M, Vasiliadou K, Ioannidou G, et al. Acral lentiginous melanoma: A case-control study and guidelines update. Case Rep Med. 2011; Article ID 670581. https://doi.org/10.1155/2011/670581
Sheppard KE. The cell-cycle regulator CDK4: An emerging therapeutic target in melanoma. Clin Cancer R
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2014 Revista Colombiana de Cirugía
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Todos los textos incluidos en la Revista Colombiana de Cirugía están protegidos por derechos de autor. Las opiniones expresadas en los artículos firmados son las de los autores y no coinciden necesariamente con las de los directores o los editores de la Revista Colombiana de Cirugía. Las sugerencias diagnósticas o terapéuticas como elección de productos, dosificación y métodos de empleo corresponden a la experiencia y al criterio de los autores.
.jpg)
